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INTRODUCTION
World Health Organization declared coronavirus disease 
(COVID-19) outbreak as pandemic on March 12, 2020. The 
2019 outbreak of Coronavirus Disease 2019 (COVID-19) was 
caused by a 2019-Novel coronavirus (2010-nCoV), later officially 
named as severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) by International Committee on Taxonomy of 
Viruses (ICTV). Like SARS-CoV and MERS-CoV, SARS-CoV-2 
also belongs to the same family of Beta coronavirus (Xei and 
Chen, 2020). World Health Organization (WHO) declared 
COVID-19 as a Public Health Emergency of International 
Concern (PHEIC) on January 30, 2020; and a pandemic on 
March 11, 2020. The severity of this pandemic has led the 
world community to implement containment measures and 
to research collaboratively to address the knowledge gaps to 
identify COVID-19 therapies (Khuroo, 2020).
Coronaviruses (CoV) consists of single-stranded RNA and 
these viruses can cause diseases to human and animals and are 
divided into four subfamilies (alpha, beta, gamma-, and delta-
CoV), with SARS-CoV-2 belonging to the beta-CoV subfamily. 
The alpha and beta coronaviruses infect mammals, the gamma 
and delta coronaviruses infect bird. Historically, six CoV have 
been previously identified as human-infecting viruses: HCoV-
229E, HCoV-0C43, SARS-CoV, HCoVNL63, HCoV-HKU1 and 
MERS-CoV (Kantar et al., 2020).
SARS-CoV-2 got its name from the crown-like carbohydrate 
covered protein spikes sticking out from a relatively large viral 
centre with a diameter of 60–140 nm. More than 1000 genomic 
sequences of COVID-19 have been globally reported in April 
2020. 27 proteins have been identified within the SARS-CoV-2 
genome; some are RNA-dependent RNA polymerase (RdRp). In 
addition, four structural proteins were shown to be encoded in 
the corona-viral genome: the nucleocapsid protein (N), a small 
envelops protein (E), the matrix proteins (M), and the spike 
surface glycoprotein (S) (Zhu, et al., 2020; Zhau et al., 2020; 
Wu et al., 2020). The genetic code of COVID-19 was shown to 
be similar to that of SARS-CoV and MERS-CoV, but differences 
in protein structures. 
No study proved due to the novel nature of the virus, which 
it will reduce men’s fertility or sexual potency but medics in 
Wuhan have suggested the likelihood that the disease can 
affect the production of low sperm count and the formation of 
male sex hormones (low libido). Also, coronavirus attacks ACE2 
receptors of the host cell which leads to COVID-19 related 
pneumonia, acute myocardial injury and chronic damage to 
the cardiovascular system (Zheng et al., 2020).
Currently, there is no vaccine or specific therapeutic agents for 
the treatment of COVID-19. Hence, it becomes a challenge to 
prevent and treat severely sick COVID-19 patients. Therefore, 
there is a requirement of effective vaccines are essential to 
combat against the deadly SARS-CoV-2. Presently, many 
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research efforts have been devoted to developing vaccines all 
over the world. The drugs which are approved by the FDA in the 
USA for other indications have been used as “repurposed” drugs 
to treat COVID-19 patients, till we have specific therapeutic 
drugs or vaccines against SARS-CoV-2. This review will give an 
idea about the most current pharmacotherapeutics prescribed 
in the treatment of severe cases of COVID-19 patients. These 
include antiviral therapy, anti-inflammatory drugs (including 
anti-arthritis drugs), neuraminidase inhibitors, antibiotics, 
systemic corticosteroids and RNA synthesis inhibitors. Yet no 
specific antiviral drugs or vaccine is available for COVID-19. 
Hence, it is very essential to combat this deadly disease, which 
requires a clear understanding of disease pathology and critical 
strategies in identifying new drugs (Renyi et al., 2020).
Drug repurposing means examining existing drugs, they will find 
therapeutic effects on new diseases. Re-purposing existing drugs, 
or even rejected drugs are required to launch that increases the 
possibility of market success as well as reducing the costs and 
time (Aggarwal et al., 2020). The use of drug re-purposing is 
that drug details, such as the stages of chemical synthesis, mass 
production processes, various stages of clinical trials and many 
more have been identified earlier. Currently, there is no drug or 
vaccine for the prevention of the SARS-CoV-2 infection, but the 
use of available antivirals can be effective against this virus. For 
example, chloroquine and remdesivir (RDV, GS-5734) are two 
drugs that in vitro studies have suggested that they can inhibit 
the viral replication (Aanouz et al., 2020; Gupta et al., 2020).
REPURPOSED DRUGS
Remdesivir
Remdesivir is an antiviral agent, formally known as GS-5734 
(Sanders et al., 2020) which was initially synthesized and 
developed by the Gilead Sciences for the treatment of Ebola 
virus infection in 2017(Pawar, 2020). Remdesivir is considered 
as a potential drug for the treatment of COVID-19. It is a 
prodrug of molecular formula C27H35N6O8P and exact 
molecular mass 602.23 Da. In the body, it is metabolized into 
its active form known as GS-441524 with a molecular formula 
C12H13N5O4 and molecular mass 291.10 Da (Siegel et al., 
2017). It is a monophosphamidate prodrug of an adenosine 
C-nucleoside having antiviral activity against several RNA 
viruses belonging to the family Coronaviridae (SARS-CoV, 
MERS-CoV), Paramyxoviridae (Nipah Virus and Hendra Virus) 
and Filoviridae (Ebola Virus; EBOV) (Amirian & Levy, 2020). 
Remdesivir is now considering the promising potential therapy 
for COVID-19 due to its broad-spectrum antiviral activity.
Remdesivir as RNA-dependent RNA polymerase (RdRp) 
inhibitor, it inhibits the replication of multiple coronaviruses 
in respiratory epithelial cells. Once the remdesivir is added to 
the growing RNA chain (i position) it cannot stop immediate 
chain termination. The presence of the 3’-hydroxyl group 
continues the addition of three more nucleotides to stop the 
RNA synthesis at (i+3) position. Thus, a possible mechanism of 
action is delayed RNA chain termination. In the recent studies, 
researchers found that almost identical results with SARS-CoV, 
MERS-CoV and SARS-CoV-2 RdRps. They found all the three 
coronavirus RdRp complexes terminate the RNA synthesis at 
(i+3) position (Gordon et al., 2020).
Since all the viruses encode polymerases in the central steps of 
replication and transcription. Thus, polymerases are becoming 
the most attractive and suitable targets for the development 
of the antiviral activity. There are two known polymerase 
inhibitors: (i) Nucleoside and nucleotide substrate analogues 
and (ii) allosteric inhibitors. Nucleoside analogues are first 
triphosphated by the host cell to produce active inhibitors 
and then act as an inhibitor by competing with the natural 
nucleoside triphosphate and terminating the growing viral 
nucleic acids. Most of the antiviral drugs which are approved for 
the treatment of HIV therapy follow this mechanism (Uzunova 
et al., 2020).
Clinical trials are ongoing to evaluate the safety and antiviral 
activity of remdesivir in patients with mild to moderate or severe 
COVID-19 (NCT04292899, NCT04292730, NCT04257656, 
NCT04252664, and NCT04280705) (Sanders et al., 2020).
The use of remdesivir was successfully done in the USA for 
COVID-19 patient. The patient was treated with remdesivir 
on the evening of the 7th day of admission (Cao et al., 2020). 
The patient’s clinical symptoms were improved after 2 days of 
the intravenous injection of the drug. It was also observed that 
their blood oxygen increased from 90% to 94%. In a recent study, 
patients with COVID-19 received remdesivir treatment for 10 
days, where on day 1, 200 mg of the drug was administered 
intravenously and 100 mg of the drug for 9 days. Clinical 
symptoms improvement and oxygen support observed in 68% 
of patients, of these 57% of patients were receiving mechanical 
ventilation and 13% of the patients died. Some adverse effects 
such as hypotension, rash, diarrhoea were observed in 57% of 
the patients who were receiving mechanical ventilation (Grein 
et al., 2020). Therefore, though remdesivir is a promising drug 
for the treatment of COVID-19, more clinical trials are required 
for the confirmation of its efficacy.
Chloroquine and Hydroxychloroquine
Quinine is obtained from the bark of cinchona trees which 
was first discovered in the 1600s and used as an antimalarial 
drug until the 1920s. During the Second World War, due to 
the inadequate amount of quinine under wartime pressure, 
synthetic drugs were derived from quinine. In 1934, German 
scientist Hans Andersag synthesized Chloroquine (CQ) as 
an anti-malarial drug. But, chloroquine was not used for 
medicinal purpose on a large scale due to its toxicity until it 
was re-synthesized by an American company and tested to be 
proved with efficacy and safety in early 1940. By introducing 
a hydroxyl group into CQ, hydroxychloroquine (HCQ) was 
synthesized in 1946, and it was approved for medical use as an 
alternative to CQ because of its favourable efficacy and reduced 
toxicity in 1955. Since then, both CQ and HCQ have been used 
broadly for the prevention and treatment of malaria and in the 
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treatment of chronic inflammatory diseases including systemic 
lupus erythematosus and rheumatoid arthritis (Browning, 2014; 
Lei et al., 2020).
The typical process of viral infection usually involves the 
following steps: endocytosis of viral particles; transport 
and uncoating leading to the release of the viral genome, 
transcription/translation/posttranslational modification of viral 
proteins and assembly followed byexocytosis. The infection 
process of COVID-19 has mediated through the interaction 
of spike (S) protein on virus and ACE2 on the host cell (Yan 
et al., 2020). CQ has been reported with the ability to inhibit 
glycosylation of the ACE2 receptor, which directly affects the 
spread of SARS-CoV infection in host cells (Vincent et al., 
2005). Moreover, recently in silico simulation showed that 
CQ/HCQ could prevent the access of S proteins to host 
cell surface ACE2 proteins by interacting with S proteins 
(Fantini et al., 2020). Therefore, inhibiting the interaction 
between S protein and ACE-2 might partially explain the 
prevention process. Additionally, CQ suppresses the expression 
of phosphatidylinositol binding clathrin assembly protein 
(PICALM), in addition, affects clathrin-mediated endocytosis 
of nanoparticles (Pelt et al., 2018). Coronavirus, after entry into 
the host cells, utilizes trypsin-like proteases in the lysosome 
to break the surface S proteins and promote the fusion with a 
lysosome in a pH-dependent manner. Due to its basic properties, 
CQ accumulates in the acidic organelles such as lysosomes, that 
will lead to a change of their acidification status (Savarino et al., 
2003).The elevated pH in lysosomes may inhibit the enzymatic 
activity of lysosome proteases and hence the infection process. 
For the treatment of COVID-19, 500 mg of chloroquine orally 
once or twice daily is recommended and for hydroxychloroquine 
dose of 400 mg twice daily for 1 day followed by 200 mg twice 
daily (Colson et al., 2020).
Chloroquine and hydroxychloroquine have been used worldwide 
for more than 75 years and listed as “Essential medicines” in the 
World Health Organization. It is cheap and established clinical 
safety profile (Cortegiani et al., 2020) but there is still a lack of 
evidence regarding the safety and effectiveness of these agents 
in treating SARS-CoV-2 (the novel virus causing COVID-19). In 
this regard, clinicians and patients should be made aware of the 
risk versus benefit profile of these medications (Juurlink, 2020).
Lopinavir/Ritonavir
Lopinavir/Ritonavir is a combined medication approved by the 
Food and Drug Administration which acts as a potent protease 
inhibitor for the treatment of HIV infection. It was identified 
in 1998 and approved in September 2000 (Yang et al., 2017). 
The combination was first marketed by Abbott under the 
brand name Kaletra in 2000. Lopinavir is available only in 
combination with Ritonavir to improve its bioavailability and 
biotransformation. Ritonavir is a potent inhibitor that helps 
in Lopinavir metabolism and improves its antiviral activity 
(Lv et al., 2015).
The protease is a homodimer containing 99 amino acids in 
each monomer and its active site contains three amino acids 
(Asp25-Thr26-Gly27) forms loop structure stabilizing the 
hydrogen bonds. The two aspartate residues (Asp 25 and Asp 
250) from both chains are involved in drug binding. Lopinavir 
binds to the active site of the protease via a strong hydrogen 
bond with the oxygen of Asp 25 and the weak hydrogen bonds 
of the carboxylic acid of Asp 250. However, lopinavir rapidly 
metabolized in the liver by CYP3A4 and CYP3A5 and lowers 
its bioavailability. Ritonavir is found to inhibit CYP450-3A4 
via its thiazole nitrogen and reduces its enzyme responsible for 
metabolizing drugs, such as antibiotics and protease inhibitors. 
Furthermore, the crystal structure of the complex CYP450-3A4/
ritonavir shows that the drug binds the active site of the enzyme 
by means of hydrophobic interactions. Therefore, ritonavir 
deactivates CYP450-3A4 and increases the bioavailability 
of certain drugs. Administration of ritonavir with lopinavir 
prohibits the metabolism of lopinavir by CYP450-3A4, which 
increases the lopinavir plasma concentration. Thus, it is used in 
the treatment of HIV infection. Lopinavir has antiviral effects 
against SARS-CoV-2. However, results from the treatment of 
patients with COVID-19 with lopinavir/ritonavir remain unclear 
(Kantar, 2020).
The dose treatment of lopinavir/ritonavir for the treatment of 
COVID-19 is 400 mg/100 mg twice daily for 14 days plus standard 
of care. No benefits were observed with lopinavir/ritonavir apart 
from the standard care. The drug-drug interactions and adverse 
drug reactions are required to be monitored if this combined 
medication is used. More common adverse effects of lopinavir/
ritonavir are diarrhoea, nausea, abdominal pain, hepatotoxicity, 
dyslipidaemias. In patients with COVID-19, these adverse 
effects may be aggravated by combination therapy or viral 
infection because approximately 20% to 30% of patients have 
elevated transaminases at presentation with COVID-19. In a 
recent clinical trial, studies showed that around 50% of lopinavir/
ritonavir patients experienced adverse effects and around 14% of 
patients stopped therapy due to gastrointestinal adverse effects 
(Cao et al., 2020).
Favipiravir
Favipiravir (T-705 or 6-fluoro-3-hydroxy-2-pyrazinecar-
boxamide) is a synthetic pyrazinecarboxamide and an antiviral 
agent designed to treat influenza (Furuta et al., 2017). It 
shows broad- spectrum antiviral activity against R dependent 
RNA polymerase (Mentre et al., 2015). Favipiravir enters the 
infected cells through endocytosis and then transformed into 
favipiravir ribofuranosyl phosphate by phosphoriborobisylation 
and phosphorylation (Renyi et al., 2020). The antiviral activity 
is exhibited by targeting the RNA dependent RNA polymerase. 
Favipiravir has been used in the treatment of infectious disease 
caused by RNA viruses such as Ebola, influenza and norovirus. 
Clinical trials have been carried out for testing favipiravir in the 
treatment of COVID-19 in various countries like China and 
Japan. The clinical trial was performed in China in between 
February 20 2020 and March 12 2020 (Trial Registration 
Number: ChiCTR2000030254)[3] showed that treatment with 
favipiravir have recovery rate around 71.43% and duration of 
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fever and cough relief time significantly shorter. However, more 
clinical trials are needed to be carried out to show whether 
favipiravir can have effective minimal antiviral activity against 
COVID-19. Some adverse effects experienced in the clinical 
trials that include higher concentration of uric acid in the serum 
with digestive tract complications (Chen et al., 2020).
Umifenovir 
Umifenovir is also known as Arbidol. Chemically it is Ethyl-
6-bromo-4-[(dimethylamino) methyl]-5-hydroxy-1-methyl-
2[(phenylsulfanyl)-methyl]-1H-indole-3 carboxylate. It is 
an indole derivative. Umifenovir is an antiviral drug that 
was licensed in Russia in 1993 and in China in 2006 for the 
treatment of influenza A and B. Umifenovir also effective 
against pH-dependent /independent viruses, such as a 
respiratory syncytial virus (Li et al., 2018). Its mechanism of 
action is similar to Imatinib, an Abelson kinase inhibitor, the 
anchor drug in the treatment of Chronic Myeloid Leukemia. 
Both of these molecules inhibit the binding of the virus to the 
cell membrane. In January 2020, clinical trial conducted in 
Wuhan, China. 36 COVID-19 patients administered 400 mg 
umifenovir three times a day for 9 days. In the control group, 
31 untreated COVID-19 patients were selected. In this clinical 
trial, treatment with umifenovir showed a tendency to reduce 
viral load determined by RT-PCR and decreased mortality, 
as compared to the control group. Combination therapy of 
umifenovir and lopinavir/ritonavir was more effective than 
lopinavir/ritonavir only. Patients treated not only with protease 
inhibitor but also with umifenovir became sooner SARS-CoV-19 
negative (Drozdzal et al., 2020). As reported by the clinical trial 
studies umifenovir might decrease the risk of SARS-CoV-19 and 
respiratory distress syndrome. Clinical trials with umifenovir 
alone or in combination with lopinavir/ritonavir have been 
recently initiated in China (Mckee et al., 2020).
Oseltamivir
Oseltamivir is approved by the Food and Drug Administration 
in 1999. It is sold under the brand name ‘Tamiflu’ and used 
in the treatment of influenza A and B. It is a neuraminidase 
inhibitor thatdistributed on the surface of the virus and inhibits 
the spread of influenza virus in the human body. There are no 
positive results were observed by the treatment of oseltamivir 
in COVID-19 patients. Clinical trials are still evaluating the 
efficacy of oseltamivir in treating SARS-CoV-2 infection. 
Oseltamivir in combination with chloroquine and favipiravir 
is also used in clinical trials (Jomah et al., 2020)
Ribavirin
Chemically ribavirin is 1-b-D-ribofuranosyl-1H-1,2,4-triazole- 
3-carboxamide. It is a purine analogue which shows antiviral 
activity against DNA and RNA viruses. Ribavirin is used in 
the treatment of hepatitis C virus (Kantar et al., 2020). It is 
usually used in combination with interferon α (IFN) (Vellingiri 
et al., 2020). Currently, ribavirin is tested for the treatment of 
COVID-19, indicated that high concentrations of ribavirin 
required to cause significant reduction in the in vitro viral 
infection.
Tocilizumab and Sarilumab
Tocilizumab and sarilumab are monoclonal antibody that 
control cytokine release syndrome which is an inflammatory 
response caused by viral infections and certain drugs (Kim et al., 
2015). Tocilizumab branded as Actembra that is humanized 
monoclonal antibodies developed by Roche and Chugai 
Pharmaceuticals for the treatment of rheumatoid arthritis. In 
China, it is expected to have a beneficial effect on coronavirus 
patient with severe lung damage and elevation in the interleukin 
6 levels. In the open-label clinical study (ChiCTR2000029765) 
21 patients with severe or critical COVID-19 infection treated 
with tocilizumab intravenously. The clinical-stage of 4 patients 
was classified as critical (19%). All patients received standard 
of care including lopinavir and methylprednisolone, as well as 
tocilizumab at a dose of 400 mg intravenously in one4 or two 
doses. 18 patients received tocilizumab twice with the second 
dose being administered due to recurrent fever within 12 hours 
of first administration. After receiving tocilizumab, all patients 
experienced fever resolution with reported improvement of 
clinical symptoms. In 75% of patients, there was a significant 
increase in the oxygen level after receiving tocilizumab on the 
fifth day. No significant adverse reactions were reported during 
the clinical trial period (Kantar et al., 2020).
Sarilumab sold under the brand name‘kefraza’ that is 
humanized monoclonal antibodies developed by the Regeneron 
Pharmaceuticals and Sanofi for the treatment of rheumatoid 
arthritis. Sarilumab is an anti interleukin 6R antibody used in the 
treatment of rheumatoid arthritis. Regeneron Pharmaceuticals 
and Sanofi in the partnership planned a randomized clinical 
trial (NCT04315298) with the Northwell Health’s Feinstein 
Institutes for Medical Research for March 2020 targeting to 
enroll 400 COVID-19 patients. Per cent change in C-protein 
and time to improve on a 7-point scale based on death and type 
of hospitalization in patients with serum interleukin 6 levels 
above a threshold as primary endpoints (Renyi et al., 2020).
Corticosteroids
Corticosteroids are commonly used in a variety of inflammatory 
conditions. Additionally, they can be used in the form of pulse 
therapy to treat flares of autoimmune diseases. However, during 
the use of corticosteroids caution is needed due to the potential 
serious side effects associated with corticosteroid drugs and that 
corticosteroids generally suppress the immune system. The 
latter means that corticosteroids modulate hyper inflammation 
and, on the other hand, inhibit immune responses that are vital 
for the host defense against the virus (Saghazadeh et al., 2020).
Dexamethasone is an old corticosteroid. It is having broad anti-
inflammatory and immunosuppressant activity that reduces 
cell-mediated immunity and inhibits cytokine production. Its 
clinical indications spread from pain in the joints to asthma, 
irritable bowel disease/Crohn disease, emesis, multiple sclerosis 
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and various autoimmune diseases, as well as different types of 
cancer, to name just the most prevalent. Dexamethasonehas 
been and is used to relieve the wheezing associated with 
COVID-19in many hospitals which were included in one 
arm of the Randomized Evaluation of COVid-19 thERapY 
(RECOVERY) trial [NCT04381936], an adaptive, multiple 
arms, randomized, controlled trial that in several months has 
enrolled more than 11,500 patients from over 175 National 
Health Service hospitals in the UK. Its immunosuppressant 
effect might benefit COVID-19 patients who experience CRS 
(Chakraborty et al., 2020).
FUTURE PERSPECTIVE
In addition to the drugs discussed in the review, many antiviral 
drugs have been explored for the treatment of COVID-19 for 
several months, without any positive effect. Other drugs tested 
for the treatment of MERS are nafamostat thymidine kinase 
inhibitors (ganciclovir and acyclovir), translation-inhibiting 
mRNA encapsulation inhibitor – ribavirin, nitazoxanide used 
to control helminthiasis and currently tested for viability in 
viral infections, another nucleotide analogue – penciclovir, as 
well as drugs known from HCV therapy (azvudine, danoprevir/
ritonavir, sofosbuvir/daclatasvir, and sofosbuvir/ledipasvir). No 
drugs which mentioned above are currently recommended 
for the treatment in SARS-CoV-2 infection. Due to the lack 
of availability of effective COVID-19 therapeutic agents, 
prevention of infection is essential. Additionally by isolating 
the sources of infection and hygienic measures, seems to be 
essential to focus on the development of a vaccine (Lythgoe & 
Middleton, 2020; Li et al., 2020).
Many of the current drugs used for the treatment of COVID-19 
patients include agents that are designed and available in the 
market for treating other viral infections, such as Malaria and 
EBOV. On the one hand, the use of repurposed drugs could be 
commercially applicable and a time-saving route; on the other 
hand, this suggests that these agents are not correct against 
COVID-19 and, hence, there is still a great deal of efficacy 
improvement through derivatization. The major problem with 
derivatization is the length of time required (at least 12–18 
months) to design, synthesize, test, and acquire approval for any 
given new drug. As a result of the economic impact as well as 
the significant death rate of COVID- 19, time is of the essence, 
and there is an immediate need to halt to interrupt the spread of 
this virus as soon as possible to avoid devastating global health 
and economic consequences. Thus, we must make do with 
currently available agents to contain the virus until treatment 
is on the market. Till the combination therapy using current 
agents helps to overcome the pandemic and should involve 
agents with significant enough activity against COVID-19 but 
with different mechanisms of action, because this will provide 
the best path towards over- coming viral resistance.
Another important aspect of this research for repurposed 
drugs involves patent protection issues under current national 
and/or international regulations. Therefore, the regulatory 
community must act to minimize any financial complications 
implicating private industry and update guidelines for drug 
licensure through repurposing if necessary. It should not escape 
us that this is a vital behind-the-scene act while efforts are 
underway to seek new indications for existing compounds 
(Novac et al., 2013).
The COVID-19 pandemic is unprecedented health, economic 
and humanitarian crisis that has a major and ongoing impact on 
people in every country around the world. It is also an example 
of the remarkable participation of scientists from every country 
united to find a cure and vaccine against one single virus, but 
also searching for future solutions (Lechowicz et al., 2020).
CONCLUSION
COVID-19 is a serious infectious disease has spread all over 
the world that is transmitted through physical contact. 
Coronavirus infects the host cell via spike protein and binds 
to the Angiotensin-Converting Enzyme 2 receptor. The most 
common symptoms of COVID-19 are fever, dry cough, tiredness 
and difficulty in breathing or shortness of breath. Researchers 
are continuously working for searching effective drugs in the 
treatment of COVID-19. Clinical trials are going for confirming 
the safety and efficacy of these repurposed drugs. Currently, 
there is no vaccine or specific treatment of antivirals for the 
treatment of COVID-19. In this review, the repurposed drugs 
mentioned having a different mechanism of action and act 
differently to combat COVID-19 infection. The repurposed 
drugs act by inhibiting viral infection by either binding to 
enzyme active sites and receptors or modulating intracellular 
signaling. No drug is having remarkable or unremarkable 
action against coronavirus but the use of the single drug may 
not be effective to control this deadly virus. So, the use of 
a combination of different antiviral agents with a different 
mechanism of action may be more effective but their adverse 
effects may not be underestimated.
ACKNOWLEDGEMENT
The authors are very thankful to the principal of P R Patil 
Institute of Pharmacy, Talegaon (SP) for valuable guidance.
REFERENCES
Aanouz, I., Belhassan, A., Khatabi, E. I., Lakhlifi, T., Idrissi, M. E., & 
Bouachrine, M. (2020). Moroccan Medicinal Plants as inhibitors 
against SARS-CoV-2 main protease: Computational investigations. 
Journal of Biomolecular Structure and Dynamics. https://doi.org/10.
1080/07391102.2020.1758790 
Aggarwal, M., Leser, G. P., & Lamb, R. A. (2020). Repurposing papaverine 
as an antiviral agent against influenza viruses and paramyxoviruses. 
Journal of Virology, 94(6), 1-14. https://doi.org/10.1128/JVI.01888-19 
Amirian, E. S., & Levy, J. K. (2020). Current knowledge about the 
antivirals remdesivir (GS-5734) and GS-441524 as therapeutic 
options for coronaviruses. One Health. https://doi.org/10.1016/j.
onehlt.2020.100128 
Browning, D. J.  (2014).  Pharmacology of Chloroquine and 
Hydroxychloroquine. In Hydroxychloroquine and Chloroquine 
Retinopathy. New York, NY: Springer. https://doi.org/10.1007/978-
1-4939-0597-3_2 
Cao, Y. C., Deng, Q., & Dai, S. (2020). Remdesivir for severe acute respiratory 
syndrome coronavirus 2 causing COVID-19: An evaluation of the 
Sonali, et al.
6 Res Pharm • 2021 • Vol 11
evidence. Travel Medicine and Infectious Disease, 35, 101647 https://
doi.org/10.1016/j.tmaid.2020.101647 
Chakraborty, R., & Parvez, S. (2020). COVID-19: An overview of the 
current pharmacological interventions, vaccines, and clinical trials. 
Biochemical Pharmacology, 180, 114184. https://doi.org/10.1016/j.
bcp.2020.114184 
Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., 
Chen, B., Lu, M., Luo, Y., Zhang, J., & Wang X. (2020). Favipiravir verses 
arbidal for COVID-19: a randomized clinical trial. MedRxiv. https://
doi.org/10.1101/2020.03.17.20037432 
Colson, P., Rolain, J. M., Lagier, J. C., Brouqui, P., & Raoult, D. (2020). 
Chloroquine and hydroxychloroquine as available weapons to find 
COVID-19. International Journal of Antimicrobial Agents, 55(4), 
105932. https://doi.org/10.1016/j.ijantimicag.2020.105932 
Cortegiani, A., Ingoglia, G., Ippolito, M., Giarrantano, A., & Einav, S. (2020). 
A systematic review on the efficacy and safety of chloroquine for the 
treatment of COVID-19. Journal of Critical Care, 57, 279-283. https://
doi.org/10.1016/j.jcrc.2020.03.005 
Drozdzal, S., Rosik, J., Lechowiz, K., Machaj, F., Kotfis, K., Ghavami, S., 
& Los, M. J. (2020). FDA approved drugs with pharmacotherapeutic 
potential for SARS-CoV-2 (COVID-19) therapy. Drug Resistance 
Updates, 53, 100719. https://doi.org/10.1016/j.drup.2020.100719 
Fantini, J., Scala, C. D., Chahinian, H., & Yahi, N. (2020). Structural and 
molecular modeling studies reveal a new mechanism of action of 
chloroquine and hydroxychloroquine against SARS-CoV-2 infection. 
International Journal of Antimicrobial Agents, 55(5), 105960. https://
doi.org/10.1016/j.ijantimicag.2020.105960
Furuta, Y., Komeno, T., & Nakamura, T. (2017). Favipiravir (T-705), a broad 
spectrum inhibitor of viral RNA polymerase. Proceedings of the Japan 
Academy, Series B Physical and Biological Sciences, 93(7), 449-463. 
https://doi.org/10.2183/pjab.93.027 
Gordon, C. J., Tchesnokov, E. P., Feng, J. Y., Porter, D. P., & Gotte, M. 
(2020). The antiviral compound remdesivir potently inhibits RNA-
dependent RNA polymerase from Middle East Respiratory Syndrome 
coronavirus. Journal of Biological Chemistry, 295(15), 4773-4779. 
https://doi.org/10.1074/jbc.AC120.013056 
Grein, J., Ohmgari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., et al. 
(2020). Compassionate use of remdesivir for patients with severe 
COVID-19. The New England Journal of Medicine, 382(24), 2327-
2336. https://doi.org/10.1056/NEJMoa2007016 
Gupta, M. K., Vemula, S., Donde, R., Gouda, G., Behera, L., & Vadde, R. 
(2020). In-silico approaches to detect inhibitors of the human severe 
acute respiratory syndrome coronavirus envelope protein ion channel. 
Journal of Biomolecular Structure and Dynamics. https://doi.org/10.
1080/07391102.2020.1751300 
Jomah, S., Asdaq, S. M. B., & Yamani, M. J. A. (2020). Clinical efficacy of 
antivirals against novel coronavirus (COVID-19) A review. Journal 
of Infection and Public Health. 2020; 13(9), 1187-1195. https://doi.
org/10.1016/j.jiph.2020.07.013 
Juurlink, D. N. (2020). Safety considerations with chloroquine, 
hydroxychloroquine and azithromycin in the management of SRAS-
CoV-2 infection. Canadian Medical Association Journal, 192(17), 
450-453. https://doi.org/10.1503/cmaj.200528 
Kantar, S. E., Nehmeh, B., Saad, P., Mitri, G., Estephan, C., Mroueh, M., 
Akoury, E., & Taleb, R. I. (2020). Derivatization and combination therapy 
of current COVID-19 therapeutic agents: a review of mechanistic 
pathways, adverse effects, and binding sites. Drug Discovery Today, 
25(10), 1822-1838. https://doi.org/10.1016/j.drudis.2020.08.002 
Khuroo, M. S. (2020). Chloroquine and Hydroxychloroquine in coronavirus 
disease 2019 (COVID-19). Facts, fiction and the hype: a critical 
appraisal. International Journal of Antimicrobial Agents, 56(3), 01-12. 
https://doi.org/10.1016/j.ijantimicag.2020.106101 
Kim, G. W., Lee, N. R., Pi, R. H., Lim, Y. S., Lee, Y. M., Jeong, H. S., & 
Chung, S. H. (2015). IL-6 inhibitors for the treatment of rheumatoid 
arthritis: Past, Present and future. Archives of Pharmacal Research, 
38(5), 575-584. https://doi.org/10.1007/s12272-015-0569-8
Lechowicz, K., Drozdezal, S., Machaj, F., Rosik, J., Szostak, B., 
Baranska, M. Z., Biernawska, J., Dabrowski, W., Rotter, I., & Kotfis, K. 
(2020). COVID-19: The potential treatment of pulmonary fibrosis 
associated with SARS-CoV-2 infection. Journal of Clinical Medicine, 
9(6), 1917. https://doi.org/10.3390/jcm9061917 
Lei, Z. N., Wu, Z. X., Dong, S., Yang, D. H., Zhang, L., Ke, Z., Zhou, C., 
& Chen, Z. S. (2020). Chloroquine and Hydroxychloroquine in 
the treatment of malaria and repurposing in treating COVID-19. 
Pharmacology and Therapeutics, 216, 107672. https://doi.
org/10.1016/j.pharmthera.2020.107672 
Li, H., Wang, Y. M., Xu, J. Y., & Cao, B. (2020). Potential antiviral therapeutics 
for 2019 Novel Coronavirus. Chinese Journal of Tuberculosis and 
Respiratory Diseases, 43(0), 170-172. https://doi.org/10.3760/
cma.j.issn.1001-0939.2020.0002 
Li, M. K., Liu, Y. Y., Wei, F., Shen, M. X., Zhong, Y., Li, S., Chen, L. J., Ma, N., 
Liu, B. Y., Mao, Y. D., Li, N., Hou, W., Xiong, H. R., & Yang, Z. Q. (2018). 
Antiviral activity of arbidal hydrochloride against herpes simplex virus 
I in vitro and in vivo. International Journal of Antimicrobial Agents, 
51(1), 98-106. https://doi.org/10.1016/j.ijantimicag.2017.09.001 
Lv, Z., Chu, Y., & Wang, Y. (2015). HIV Protease inhibitors: a review of 
molecular selectivity and toxicity. HIV/AIDS- Research and Palliative 
Care, 7, 95-104. https://doi.org/10.2147/HIV.S79956 
Lythgoe, M. P., & Middleton, P. (2020). Ongoing clinical trials for the 
management of COVID-19 pandemic. Trends Pharmacological 
Sciences, 41(6), 363-382. https://doi.org/10.1016/j.tips.2020.03.006
McKee, D. L., Sternberg, A., Stange, U., Laufer, S., & Naujokat, C. (2020). 
Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacological 
Research, 157, 104859. https://doi.org/10.1016/j.phrs.2020.104859
Mentre, F., Taburet, A. M., Guedj, J., Anglaret, X., Keita, S., Lamballerie, X. D., 
& Malvy, D. (2015). Dose regimen of favipiravir for Ebola virus 
disease. The Lancet, infectious Diseases, 15(2), 150-151. https://doi.
org/10.1016/S1473-3099(14)71047-3 
Novac, N. (2013). Challenges and opportunities of drug repositioning. 
Trends in Pharmacological Sciences, 34(5), 267-272. https://doi.
org/10.1016/j.tips.2013.03.004
Pawar, A. Y. (2020). Combating devastating COVID-19 by drug repurposing. 
International Journal of Antimicrobial Agents, 56(2), 01-04. https://
doi.org/10.1016/j.ijantimicag.2020.105984 
Pelt, J., Busatto, S., Ferrari, M., Thompson, E. A., Mody, K., & Wolfram, J. 
(2018). Chloroquine and nanoparticle drug delivery: A Promising 
combination. Pharmacology and Therapeutics, 191, 43-49. https://
doi.org/10.1016/j.pharmthera.2018.06.007
Renyi, W., Wang, L., Kuo, H. C. D., Ahmad, S. A., Peter, R., Chou, P. J., Li, S., 
Hudlikar, R., Liu, X., Liu, Z., Poiani, G. J., Amorosa, L., Brunetti, L., & 
Kong, A. N. (2020). An update on current therapeutic drugs treating 
COVID-19. Current Pharmacology Reports, 6, 56–70 https://doi.
org/10.1007/s40495-020-00216-7 
Saghazadeh, A., & Rezaei, N. (2020). Towards treatment planning of 
COVID-19: Rationale and hypothesis for the use of multiple 
immunosuppressive agents: Anti-antibodies, immunoglobulins, and 
corticosteroids. International Immunopharmacology, 84, 106560. 
https://doi.org/10.1016/j.intimp.2020.106560
Sanders, J. M., Marguerite, L. M., Jodlowski, T. Z., & Cutrell, J. B. (2020). 
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) 
A review. Journal of American Medical Association, 323(18), 1824-
1836. https://doi.org/10.1001/jama.2020.6019 
Savarino, A., Boelaert, J. R., Cassone, A., Majori, G., & Cauda, R. (2003). 
Effects of chlroquine on viral infections: An old drug against today’s 
diseases. The Lancet, Infectious Diseases, 3(11), 722-727. https://doi.
org/10.1016/s1473-3099(03)00806-5 
Siegel, D., Hui, H. C., Doerffler, E., Clarke, M. O., Chun, K., Zhang, L., 
Neville, S., Carra, E., & Solovena, V. (2017). Discovery and synthesis of 
a phosphamidate prodrug of a pyrrolol [2, 1-f][triazin-4-amino] adenine 
C-nucleoside (GS-5734) for the treatment of Ebola and emerging 
viruses. Journal of Medicinal Chemistry, 60(5), 1648-1661. https://
doi.org/10.1021/acs.jmedchem.6b01594 
Uzunova, K., Filipova, E., Pavlova, V., & Vekov, T. (2020). Insights into antiviral 
mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/
hydroxychloroquine affecting the new SARS-CoV-2. Biomedicine 
and Pharmacotherapy, 131, 110668 https://doi.org/10.1016/j.
biopha.2020.110668 
Vellingiri, B., Jayaramayya, K., Iyer, M., Narayanasamy, A., Govindasamy, V., 
Giridharan, B., Ganesan, S., Venugopal, A., Venkatesan, D., 
Ganesan, H., Rajagopalan, K., Rahman, P., Cho, S. G., Kumar, N. S., 
& Subramaniam, M. D. (2020). COVID-19: A promising cure for the 
global panic. The Science of the Total Environment, 725, 138277. 
https://doi.org/10.1016/j.scitotenv.2020.138277 
Vincent, M. J., Bergeron, E., Benjannet, S., Erickson, B. R., Rollin, P. E., 
Ksiazek, T. G., Seidah, N. G., & Nichol, S. T. (2005). Chloroquine is a 
potent inhibitor of SARS coronavirus infection and spread. Virology 
Journal, 2, 69. https://doi.org/10.1186/1743-422X-2-69 
Wu, A., Peng, Y., Huang, B., Ding, X., Wang, X., Niu, P., Meng, J., Zhu, Z., 
Sonali, et al.
Res Pharm • 2021 • Vol 11  7 
Zhang, Z., Wang, J., Sheng, J., Quan, L., Zanzian, X., Tan, W., Cheng, 
G., & Jiang T. (2020). Genome composition and divergence of the 
novel coronavirus (2019-nCoV) originating in China. Cell Host and 
Microbe, 27(3), 325-328. https://doi.org/10.1016/j.chom.2020.02.001 
Wu, R., Wang, L., Kuo, H. D., Shannar, A., Peter, R., Chou, P. J., Li, S., 
Hudlikar, R., Liu, X., Liu, Z., Poiani, G. J., Amorosa, L., Brunetti, L., & 
Kong, A. N. (2020). An Update on Current Therapeutic Drugs Treating 
COVID-19. Current Pharmacology Reports, 1–15. Advance online 
publication. https://doi.org/10.1007/s40495-020-00216-7
Xie, M., & Chen, Q. (2020). Insight into 2019 novel coronavirus- an 
updated interim review and lessons from SARS-CoV and MERS-CoV. 
International Journal of Infectious Diseases, 94,119-124. https://doi.
org/10.1016/j.ijid.2020.03.071 
Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., & Zhou, Q. (2020). Structural basis 
for the recognition of SARS-CoV-2 by full length ACE2. Science, 
367(6485), 1444-1448. https://doi.org/10.1126/science.abb2762 
Yang, W., Xiao, Q., Wang, D., Yao, C., & Yang, J. (2017). Evaluation of 
pharmacokinetic interactions between long-acting HIV-1 infusion 
inhibitor albuvirtide and lopinavir/ritonavir, in HIV-infected subjects, 
combined with clinical study and simulation results. Xenobiotica, 
47(2), 133-143. https://doi.org/10.3109/00498254.2016.1166532 
Zhau, P., Yang, X. L., & Zheng, L. S. (2020). A Pneumonia outbreak associated 
with a new coronavirus of probable bat origin. Nature, 579, 270-273. 
https://doi.org/10.1038/s41586-020-2012-7 
Zheng, Y., Ma, Y.T., Zhang, J.Y., & Xie, X. (2020). COVID-19 and the 
cardiovascular system. Nature Reviews Cardiology, 17, 259-260. 
https://doi.org/10.1038/s41569-020-0360-5 
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., 
Shi, W., Lu, R., & Niu, P. (2020). A Novel coronavirus from patients with 
pneumonia in China, 2019. The New England Journal of Medicine, 
382(8), 727-733. https://doi.org/10.1056/NEJMoa2001017
